TAS-117 by Taiho Pharmaceutical for Chondrosarcoma: Likelihood of Approval

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II…

Jun 11, 2023 - 20:00

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs for Chondrosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TAS-117 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAS-117 overview

TAS-117 is under development for the treatment of solid tumors including FGFR1 squamous cell lung cancer, ovarian clear cell carcinoma, endometrial cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, head and neck cancer, thyroid cancer, chondrosarcoma and g-PTEN aberrations cancer. It is a small molecule administered by orally. The drug candidate acts as selective non-ATP competitive inhibitor of AKT. It was under development for the treatment of gastric cancer and multiple myeloma.

Taiho Pharmaceutical overview

Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, immunology, allergy and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.

For a complete picture of TAS-117’s drug-specific PTSR and LoA scores, buy the report here.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow